Disposable sensor revenue comprised 94% of total revenue for the three months ended June 30, 2024, compared to 89% for the same period in 2023. This highlights the company's strategic focus on disposable sensors as a key growth driver.

International revenue increased by 7% year-over-year to $272.4 million in Q2 2024, representing 27% of total revenue. This growth indicates the success of Dexcom's international expansion strategy.

In March 2024, Dexcom received marketing clearance from the FDA on Stelo, a new 15-day sensor designed for people with Type 2 diabetes who do not use insulin. This expands Dexcom's addressable market.

Total operating expenses as a percentage of revenue decreased from 48% in Q2 2023 to 47% in Q2 2024. This indicates improved operational efficiency and cost management.

Research and development expenses increased by 14% year-over-year to $136.0 million in Q2 2024. Management believes these investments are critical for future growth and maintaining a competitive position.

In July 2024, the Board of Directors authorized a share repurchase program of up to $750.0 million. This demonstrates confidence in the company's financial position and future prospects.

Dexcom and Abbott continue to engage in patent litigation in multiple jurisdictions. The outcome of these legal proceedings could have a material adverse effect on Dexcom's business, financial condition, or results of operations.

The company acknowledges that there is no guarantee that the share repurchase program will have a positive impact on the stock price or earnings per share.

The company acknowledges that it will be exposed to additional foreign currency exchange risk related to its international operations as it expands its manufacturing internationally and as its business continues to increase in international markets.

The ongoing patent litigation with Abbott, as detailed in Item 1, highlights the competitive landscape and the importance of intellectual property in maintaining market position.

The FDA clearance of Stelo, a glucose biosensor for people with Type 2 diabetes not using insulin, positions Dexcom to compete in a broader market segment.

Management emphasizes the importance of focused investments in research and development for future growth and competitive positioning.

Operating expenses decreased from 48% of revenue in Q2 2023 to 47% in Q2 2024, indicating improved operational efficiency.

The decrease in gross profit margin percentage in the second quarter of 2024 compared to the second quarter of 2023 was primarily driven by product and channel mix changes.

The company expects to have significant capital expenditures for the next year to scale-up capacity in Mesa, Arizona and drive strategic initiatives of building out manufacturing facilities in Malaysia and Ireland.

Research and development expenses increased by 14% year-over-year to $136.0 million. These investments are focused on sensing technology, clinical trials, and regulatory expenses.

Dexcom plans to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration.

Dexcom intends to expand efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior.

The Board of Directors authorized a share repurchase program of up to $750.0 million, signaling confidence in the company's financial health and commitment to returning value to shareholders.

The company expects significant capital expenditures in the next year to scale-up capacity in Mesa, Arizona and build out manufacturing facilities in Malaysia and Ireland.

Management emphasizes that focused investments in research and development are critical to the company's future growth and competitive position.

The 10-Q filing does not explicitly discuss any environmental, social, or governance initiatives undertaken by the company during the reporting period.

The company typically experiences seasonality, with lower sales in the first quarter of each year compared to the immediately preceding fourth quarter. This seasonal sales pattern relates to U.S. annual insurance deductible resets and unfunded flexible spending accounts.

The company has assessed the impact of the Organization for Economic Co-operation and Development's (OECD) framework to implement a global minimum corporate tax of 15% (Pillar 2) on its financial statements and the impact is immaterial.

In June 2024, the State of California enacted S.B. 167, which suspends the use of net operating losses (“NOLs”) for the tax period from January 1, 2024 to December 31, 2026 for net business income of $1 million or more, as well as limits the utilization of research and development tax credits to $5 million each year.